Literature DB >> 28437868

Early mortality and overall survival of acute myeloid leukemia based on facility type.

Vijaya R Bhatt1, Valerie Shostrom2, Smith Giri3, Krishna Gundabolu1, K M Monirul Islam4, Frederick R Appelbaum5, Lori J Maness1.   

Abstract

Cancer health disparities may exist based on the facility type. We aimed to determine the association between the academic status of centers and outcomes of patients with acute myeloid leukemia (AML). Using the National Cancer Data Base, we compared 1-month mortality and long-term overall survival (OS) of 60 738 patients with AML, who received first course treatment between 2003 and 2011 at academic or nonacademic centers (community cancer program, comprehensive community cancer program, and others). Multivariate analysis was done using logistic regression for one-month mortality and Cox regression with backward elimination approach for OS. Patients treated at academic centers differed from those at nonacademic centers in that they were younger with a median age of 62 versus 70 years (P < .0001), more often an ethnic minority (P < .0001), had lower education level (P = .005), lower co-morbidity score (P < .0001), a different income (P < .0001), and insurance profile (P < .0001), and more often received chemotherapy (P < .0001) and transplant (P < .0001). Receipt of care at nonacademic centers was associated with worse 1-month mortality (29% vs. 16%, P < .0001) and 5-year OS (15% vs. 25%; P < .0001). After adjusting for prognostic covariates, the 1-month mortality (odds ratio, 1.52; 95% confidence interval, CI 1.46-1.59; P < .0001) and OS were significantly worse in nonacademic centers, compared to academic centers. Our large database study suggests that the receipt of initial therapy at academic centers is associated with lower 1-month mortality and higher long-term OS. Investigation of the underlying reasons may allow reducing this disparity.
© 2017 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2017        PMID: 28437868     DOI: 10.1002/ajh.24767

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  20 in total

1.  Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States.

Authors:  Vijaya Raj Bhatt; Valerie Shostrom; Krishna Gundabolu; James O Armitage
Journal:  Blood Adv       Date:  2018-06-12

2.  Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients.

Authors:  Joel M Michalski; Elizabeth R Lyden; Andrea J Lee; Zaid S Al-Kadhimi; Lori J Maness; Krishna Gundabolu; Vijaya Raj Bhatt
Journal:  Future Oncol       Date:  2019-06-07       Impact factor: 3.404

3.  Cancer in older adults: understanding cause and effects of chemotherapy-related toxicities.

Authors:  Vijaya R Bhatt
Journal:  Future Oncol       Date:  2019-07-24       Impact factor: 3.404

4.  Early mortality and survival in older adults with acute myeloid leukemia.

Authors:  Manisha Pant; Vijaya Raj Bhatt
Journal:  Int J Hematol Oncol       Date:  2017-11-20

5.  Treatment patterns and outcomes of octogenarian patients with acute myeloid leukemia.

Authors:  Vijaya R Bhatt; Valerie Shostrom; James O Armitage; Krishna Gundabolu
Journal:  Am J Hematol       Date:  2019-04-01       Impact factor: 10.047

6.  Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States.

Authors:  Amer M Zeidan; Nikolai A Podoltsev; Xiaoyi Wang; Chi Zhang; Jan Philipp Bewersdorf; Rory M Shallis; Scott F Huntington; Natalia Neparidze; Smith Giri; Steven D Gore; Amy J Davidoff; Xiaomei Ma; Rong Wang
Journal:  Blood Adv       Date:  2020-04-28

Review 7.  The cure of leukemia through the optimist's prism.

Authors:  Hagop M Kantarjian; Nitin Jain; Guillermo Garcia-Manero; Mary Alma Welch; Farhad Ravandi; William G Wierda; Elias J Jabbour
Journal:  Cancer       Date:  2021-10-06       Impact factor: 6.860

8.  Survival of Older Adults With Newly Diagnosed Acute Myeloid Leukemia: Effect of Using Multiagent Versus Single-agent Chemotherapy.

Authors:  Vijaya R Bhatt; Valerie Shostrom; Sarah A Holstein; Zaid S Al-Kadhimi; Lori J Maness; Ann Berger; James O Armitage; Krishna Gundabolu
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-02-04

9.  Distance to treatment center is associated with survival in children and young adults with acute lymphoblastic leukemia.

Authors:  Seth J Rotz; Wei Wei; Stefanie M Thomas; Rabi Hanna
Journal:  Cancer       Date:  2020-09-10       Impact factor: 6.860

10.  Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia.

Authors:  Anand P Jillella; Martha L Arellano; Manila Gaddh; Amy A Langston; Leonard T Heffner; Elliott F Winton; Morgan L McLemore; Chao Zhang; Catherine R Caprara; Kathryn S Simon; Sheldon L Bolds; Stephanie DeBragga; Prachi Karkhanis; Shruthi H Krishnamurthy; Jose Tongol; Mohamed M El Geneidy; Asim Pati; Jonathan M Gerber; Michael R Grunwald; Jorge Cortes; Asad Bashey; Robert K Stuart; Vamsi K Kota
Journal:  JCO Oncol Pract       Date:  2020-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.